Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

belvarafenib

Drug and asset intelligence for belvarafenib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Recent signals(1)

ClinicalJuly 5, 2026

Genentech's Belvarafenib Trial in NRAS-mutant Advanced Melanoma Initiated

A study is underway to evaluate belvarafenib's safety and activity as a monotherapy and in combination with cobimetinib and nivolumab in NRAS-mutant advanced melanoma patients.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Roche — belvarafenib

Key milestones include interim results and safety data releases from the trial.

July 5, 2026 · N/A

Indications

NRAS-mutant Melanoma →

Therapeutic areas

NRAS-mutant Melanoma →

Oncology · NRAS-mutant Melanoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.